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Nitrogen oxide-containing compounds displaced the peripheral benzodiazepine ligand [3H]Ro5-4864 from guinea pig membrane preparations. Sodi- 
um nitroprusside (SNP) was the most potent ([Cm= 5.61+ 1.72 x lO-5 M). Moreover, its ability to bind to these receptors howed marked tissue 
variability (heart > kidney >> cerebral cortex). When tested on rat atrium, SNP by itself had no effect on basal inotropy or the increase in inotropy 
induced by (-)-S-BAY K 8644. In contrast, Ro5-4864 potentiated the marked increase in inotropy induced by (-)-S-Bay K 8644, and SNP com- 
pletely abolished the potentiation of inotropy observed with Ro5-4864. Since peripheral benzodiazepine receptors are associated with calcium 
mobilization in the heart, these findings may indicate that some of the clinical effects of nitric oxide-generating drugs could be mediated by these 
receptors. 
Benzodiazepine r ceptor, peripheral; Sodium nitroprusside; (Rat atrium; Guinea pig heart) 
1. INTRODUCTION 
Peripheral benzodiazepine receptors (PBR) ex- 
hibiting high affinity for [3H]Ro5-4864 have been 
demonstrated in a wide variety of mammalian tissues 
[l-3]. The pharmacological profile and distribution of 
these receptors are distinct from those of central ben- 
zodiazepine receptors which mediate the effects of ben- 
zodiazepine agonists, e.g. diazepam, clonazepam [4]. 
Several lines of evidence indicate that PBR ligands af- 
fect calcium-dependent events in the guinea pig and rat 
heart [5-7,8] and mediate ventricular arrhythmias dur- 
ing myocardial ischemia in the dog [9]. Moreover, 
studies performed using cell cultures and synaptosomal 
preparations showed that PBR ligands may be 
associated with and modulate Ca2+ uptake via voltage- 
dependent calcium channels (VDCC) [lo- 121. 
tent vascular smooth muscle relaxing drug, inhibits the 
norepinephrine-induced 45Ca2+ uptake in rat aortic 
strips. Most of the investigations studying the 
mechanism of action of nitrovasodilators have focused 
on the activation of guanylate cyclase [16], leaving 
other pathways poorly explored. 
The present study describes an interaction between 
SNP and other nitrovasodilators with PBR in the 
guinea pig heart and the spontaneously beating rat 
atrium. We now report that these agents displace PBR 
ligands from guinea pig heart membrane preparations 
and that SNP inhibits the modulation of VDCC by 
RoS-4864 in the rat atrium. 
2. MATERIALS AND METHODS 
2.1. Tissue preparation and radioligand binding 
A large group of experimental and clinically useful 
vasodilators are thought to act by generating nitric ox- 
ide (NO) which in turn increases cyclic GMP (cGMP) 
production resulting in a modulation of intracellular 
calcium levels [13-151. Recently, Karaki et al. [15] 
demonstrated that sodium nitroprusside (SNP), a po- 
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Male Hartley guinea pigs (250-300 g, Charles River, Wilmington, 
MA) were killed by decapitation and the heart kidney and brain were 
rapidly excised and placed in ice-cold 10 mM Hepes/tS% sucrose, 
pH 7.4 buffer. Following the removal of surrounding tissues from the 
heart and the dissection of the cerebral cortex, membranes were 
prepared as described by Sulakhe et al. [17] and frozen at -70°C un- 
til use. Thawed aliquots were resuspended in 250, 400 and 100 vols 
of 50 mM Tris-HC!, pH 7.4 buffer for heart, kidney and cerebral 
cortex, respectively, and 0.25 ml of membrane suspension added to 
each assay tube. 
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[3H]Ro5-4864 (specific activity 79.7 Ci/mmol, New England 
Nuclear, Boston, MA) binding experiments were carried out in a total 
assay volume of 1 ml. In most studies, membrane preparations and 
drugs were incubated first at 30°C for 10 min, next transferred to an 
ice bath, radioligand added and the incubation continued at 0-4°C 
for 1 h. Binding was terminated by rapid filtration and two 5-m! 
washes with ice-cold buffer over Whatman GF/B glass fiber filters 
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using a Brandel M-24R cell harvester (Brandel, Gaithersburg, MD). 
Non-specific binding was determined in the presence of 5 x 10e6 M 
PK 11195. Radioactivity was measured using a Packard scintillation 
spectrophotometer, model 2000 CA/LL. ICSO values and Hill coeffi- 
cients were determined by the GRAFCAL IBM-PC computer pro- 
gram (Kaplan, D., Israel Institute for Biological Research, Israel). 
2.2. Intact tissue studies 
Male Sprague-Dawley rats weighing 175-200 g (Charles River, St. 
Constant, Quebec) were killed by decapitation. For the preparation 
of the atrium, hearts were rapidly removed and placed into a 
physiological salt solution (PSS), which was equilibrated with 95% 
00% COZ, pH 7.2 at 37°C. The PSS had the following composi- 
tion (in mM): 137 NaCl, 2.7 KCl, 1.8 CaCl2, 0.49 MgCl2, 0.35 
NaH2P04, 5.6 dextrose and 11.9 NaHCO3. The right and left atrium 
were dissected free from surrounding tissues and mounted with 0.5 g 
tension to a high compliance strain gauge transducer (Grass Model 
FT03C, Grass Instruments) in a 20 ml organ bath containing PSS at 
37°C equilibrated with 95% 02/5% COz. Atria1 tissues were 
equilibrated for 60 min at 37°C with one change of bath medium 
every 15 min before any drug addition(s). 
2.3. Materials 
Specific drugs were obtained as follows: Ro5-4864, Hoffman- 
LaRoche, Nutley, NJ; PK 11195, Pharmuka Laboratories, 
Genevilliers, France; (-)-S-BAY K 8644, Miles Institute for 
Preclinical Pharmacology, West Haven, CT. All other chemicals 
were obtained from standard commercial sources. 
3. RESGLTS 
3.1. Radioligand binding studies 
SNP had only a marginal effect on the binding of 
[3H]Ro5-4864 to guinea pig heart membranes in- 
cubated at 0-4°C for 1 h (less than 20% inhibition at 
a concentration of low3 M). Preincubation of SNP 
with heart tissue for 10 min at 30°C followed by the ad- 
dition of radioligand and continuation of the reaction 
for 1 h at 0-4°C resulted in a concentration-dependent 
inhibition of [3H]Ro5-4864 binding. The ZCSO value for 
SNP in this preparation was 5.6 f 1.7 x lo-’ M and 
the Hill coefficient 0.55 f 0.06 (n = 8). The potency of 
sodium nitroprusside was the highest in the heart and 
was one or two orders of magnitude lower in kidney 
and cerebral cortex membranes, respectively (table 1). 
Other nitric oxide-generating agents, such as hydrox- 
ylamine (ZCSO value of 5.12 & 1.86 x 10m4 M), displac- 
ed [3H]Ro5-4864 from its binding sites on cardiac 
membranes but demonstrated a significantly lower 
potency compared to SNP (table 2). The clinically 
useful drug isosorbide dinitrate (ISDN) showed a lower 
activity with an ZC50 of 8.7 + 1.5 x 10e4 M, which was 
somewhat higher than that of 4-nitroquinoline-N- 
oxide. Potassium ferricyanide, a substance known to 
inhibit guanylate cyclase activated by SNP, was about 
200-fold less active than SNP in displacing 
[‘H]Ro5-4864 from guinea pig heart membranes. Two 
other nitrogen oxide-containing chemicals, NaNO2 and 
NaNO3, were only marginally active (table 2), while 
NaCN was completely inactive at a concentration of 
1O-2 M. 
Table 1 
Inhibition of [‘H]RoS-4864 binding to PBR by SNP 
Heart Kidney Cerebral cortex 
ZCso (M) 5.61 + I.72 x lo-’ 3.0 k 0.2 x lO-4 3.7 f 0.3 x lO-3 
Hill co- 
efficient 0.55 + 0.06 0.67 f 0.05 0.44 f 0.14 
Data are presented as the mean f SE of 3-8 experiments performed 
as described in section 2. The t3H]Ro5-4864 final concentration was 
The Hill coefficients of all the substances tested were 
close to 0.5 and significantly different from 1 .O (tables 
1,2; fig. l), suggesting multiple-site interaction(s) or 
negative cooperativity. In contrast, PK 11195, a potent 
antagonist at PBR, displaced [3H]Ro5-4864 from heart 
membrane preparations with an ZCSO value of 2.43 + 
0.27 x lo-’ M and a Hill coefficient of 1.06 + 0.06 
(n = 5). Additionally, SNP and hydroxylamine displac- 
ed [‘H]PK 11195 from guinea pig heart membrane 
1 nM in all tissues examined 
Table 2 
Effects of various compounds on the binding of [‘H]Ro5-4864 to 
guinea pig heart membranes 
~ 100 -
5 
$ 
=: llo- 
% 
+ 
= 60- 
E 
Agent &o (M) Hill coefficient 
SNP 5.61 f 1.72 x lO-5 0.55 + 0.06 
Hydroxylamine 5.12 + 1.68 x lO-4 0.56 + 0.05 
ISDNa 8.7 k 1.5 x lO-4 0.65 f 0.06 
4-NQNOb 2.0 + 0.2 x 10-s 0.68 f 0.08 
IWe(C (52.9)C 
NaNOz (43.2)’ 
NaN03 (25.4)’ 
a Isosorbide dinitrate 
b 4-Nitroquinoline-N-oxide 
’ Percent inhibition at lo-’ M 
Data are presented as mean i SE of 4-8 separate determinations. 
Binding assays were carried out as described in section 2 with a final 
log lilisplacerl (Ml 
Fig.1. Inhibition of the binding of t3H]Ro5-4864 to membranes of 
guinea pig heart by sodium nitroprusside (0) and hydroxylamine 
(x). Heart membranes were prepared as described in section 2.1. 
Shown are data from one experiment repeated 4-8 times with 
ligand concentration of 1 nM identical results. The final ligand concentration was 1 nM. 
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Table 3 
Modulation of (-)-S-BAY K 8644-induced inotropy in the 
spontaneously beating rat atrium 
Agent(s) Chronotropy Inotropy 
(beats/min) (070 of basal response) 
Control 240 + I 
(- )-S-BAY K 8644 300 f lSa 135 f 32a 
+ SNP 298 f 14a 128 + 13a 
+ Ro5-4864 291 f Sa 237 f 33ab 
+ Ro5-4864 + SNP 270 + 12a 141 f 22a 
a Significantly different from control, P < 0.05 
b Significantly different from (-)-S-BAY K 8644, P < 0.05, 
Student’s t-test 
Results are presented as the mean k SE of 3-s measurements (n = 
7-10). SNP (100 PM) and Ro5-4864 (10 PM) were incubated for 
10 min before the incubation of (-)-S-BAY K 8644 (1 PM) (5 min). 
Inotropy is presented as the percent increase compared to control 
force of contraction 
preparations with If30 values similar to those observed 
using [3H]Ro5-4864 (results not shown). 
In another set of experiments, it was observed that 
the binding of tritiated N-methylscopolamine 
(t3H]NMS), a muscarinic antagonist, was not affected 
by concentrations of SNP above 10m3 M (results not 
shown). 
3.2. Intact tissue studies 
In order to further examine the interaction(s) be- 
tween SNP and PBR in intact tissues, a spontaneously 
beating rat atrium was used. The atrium was incubated 
in an organ bath in the presence of the calcium channel 
activator ( - )-S-BAY K 8644. A concentration of 1 ,uM 
( -)-S-BAY K 8644 induced a 135% increase in the 
force of contraction (i.e. inotropy) (table 3). SNP and 
RoS-4864 (100 and lO/cM, respectively) had no effect 
on basal chronotropy or inotropy. A high concentra- 
tion of SNP (100 PM) did not alter the chronotropy or 
inotropy induced by (-)-S-BAY K 8644, whereas 
RoS-4864 (10 pM) significantly potentiated the in- 
otropic response to (-)-S-BAY K 8644 by 2-fold. 
However, SNP completely inhibited the inotropic ac- 
tion of RoS-4864 when added together (table 3). None 
of the drugs used had any effect on the positive 
chronotropic effect elicited by (-)-S-BAY K 8644. 
4. DISCUSSION 
SNP is a potent vasodilator acting as a vascular 
smooth muscle relaxing drug [12,15,16,21]. This drug 
has been shown to potently increase cGMP levels in 
various cell systems [161. In addition, other agents har- 
ing a similar pharmacological profile, e.g. ISDN, 
hydroxylamine, have also been shown to elicit cGMP 
accumulation [ 181. Recent studies have demonstrated 
that the activity of nitrovasodilators [16] on muscle 
cells is associated with a decrease in the level of in- 
tracellular calcium [ 151, apparently as a consequence of 
cGMP accumulation [ 131. The processes involved in 
this pathway, culminating in the relaxation of the 
smooth muscle, may be a direct (or indirect) result of 
the interaction between nitrogen oxide(s) and 
sulfhydryl groups [13,14,16]. 
The guinea pig heart was selected for the study since 
it has been shown to possess a high density of PBR [7] 
that are functionally linked to voltage-dependent 
calcium channels [5-71. Data presented in table 1, 
demonstrate that SNP exhibited a marked tissue 
specificity as evidenced by the differential binding af- 
finities to membranes prepared from heart, kidney and 
cerebral cortex. The ability of SNP to displace 
[3H]Ro5-4864 from PBR in heart membrane prepara- 
tions was 19- and 151-fold higher than in renal and 
cerebral cortex membranes, respectively. Furthermore, 
the I& values in heart of SNP and other substances in- 
vestigated in this study are similar to the concentrations 
and doses required to elicit cGMP formation [19,20] 
and reduce blood pressure, respectively [21]. 
The effects of SNP on peripheral benzodiazepine 
receptors in guinea pig heart membranes appeared to be 
specific, as concentrations of this drug higher than its 
I& for [3H]Ro5-4864 binding did not affect the bin- 
ding of [3H]NMS. An additional aspect of the specifici- 
ty of SNP [NazFe(NO)(CN)a] at PBR is evident from 
the observations regarding the lack or marginal activity 
of compounds such as NaCN, NaN03 and NasFe(CN)e 
(table 2). Although these substances hare some of the 
same chemical functions, they differ dramatically from 
SNP in their potency to displace [3H]Ro5-4864 from 
cardiac tissue. 
A functional relationship between PBR and SNP is 
indicated by observations reported in table 3. PBR 
ligands have been shown to interact with voltage- 
dependent calcium channels in their activated state 
both in vitro [6,7,22] and in vivo [8,9,22]. In the spon- 
taneously beating rat atrium, a tissue which responds to 
Ro5-4864 and (-)-S-BAY K 8644 in an identical man- 
ner to guinea pig atrium (Bolger, G.T., unpublished 
results), SNP did not alter either basal or (-)-S- 
BAY K 8644-activated states. However, the potentia- 
tion of the positive inotropic effect of (-)-S- 
BAY K 8644 by Ro5-4864 was completely abolished by 
SNP (table 3). 
It should be noted that the effects of SNP and all 
other compounds examined with regard to 
[3H]Ro5-4864 binding were detected following prein- 
cubation at 30°C. Under such conditions nitric oxide or 
other reactive nitrogen oxide intermediates may be 
released and react with thiol groups on membranous 
protein(s), forming labile S-nitrosothiols [13,14]. The 
generation of such compounds can elicit alterations in 
PBR binding characteristics. Benavides et al. 1231 and 
Lueddens et al. [24] reported on the effects of the 
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histidine-modif~ng reagent dietbylpyroc~boxylate 
and of AHN 086, a specific alkylating agent of PBR, 
respectively. In these studies the interaction of a reac- 
tive chemical with rat kidney PBR produced dramatic 
alterations in the binding of the PBR Iigand PK 11195. 
Our results demonstrate that thiol groups localized on 
or in the vicinity of the PBR may affect significantly 
the binding of [3H]RoS-4864, as do histidine moieties. 
Thus, several lines of evidence suggest hat SNP, a 
potent vasodilator, as well as other nitrovasodilators, 
interact with PBR on cardiac tissue. Since PBR are 
associated with calcium mobilization, our findings may 
indicate that the clinical effects (vasodilatation) of 
nitrogen oxide-containing drugs could be mediated by 
an interaction with PBR and an inhibition of calcium 
mobilization. 
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